Cellular senescence in ageing: from mechanisms to therapeutic opportunities.
Nature reviews. Molecular cell biology
confidence
Key findings
Review of cellular senescence mechanisms and therapeutic opportunities (senolytic/senomorphic therapies); no reported clinical or biological endpoints.
View source on PubMed (PMID 33328614) ↗
- Population
- Review article (no clinical population)
- Blinding
- not_reported
- Controls
- not_reported
- Drug class
- senolytic class
Full abstract
Cellular senescence, first described in vitro in 1961, has become a focus for biotech companies that target it to ameliorate a variety of human conditions. Eminently characterized by a permanent proliferation arrest, cellular senescence occurs in response to endogenous and exogenous stresses, including telomere dysfunction, oncogene activation and persistent DNA damage. Cellular senescence can also be a controlled programme occurring in diverse biological processes, including embryonic development. Senescent cell extrinsic activities, broadly related to the activation of a senescence-associated secretory phenotype, amplify the impact of cell-intrinsic proliferative arrest and contribute to impaired tissue regeneration, chronic age-associated diseases and organismal ageing. This Review discusses the mechanisms and modulators of cellular senescence establishment and induction of a senescence-associated secretory phenotype, and provides an overview of cellular senescence as an emerging opportunity to intervene through senolytic and senomorphic therapies in ageing and ageing-associated diseases.